Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536464 | 1.00 | RHEB (0.32) | RHEBALDH1A1HPGDPTGS1PTGS2 | |
| SCHEMBL20536427 | 0.89 | SMN1; SMN2 (0.32) | HPGDSTK39 | |
| SCHEMBL20536428 | 0.89 | SMN1; SMN2 (0.32) | HPGDSTK39 | |
| SCHEMBL29015530 | 0.82 | KMO (0.39) | STK39 | |
| SCHEMBL29015560 | 0.77 | HTT (0.49) | ALDH1A1HPGD | |
| SCHEMBL19331303 | 0.77 | LMNA (0.40) | ALDH1A1PTGS2 | |
| SCHEMBL19331299 | 0.77 | LMNA (0.40) | ALDH1A1PTGS2 | |
| SCHEMBL19330849 | 0.76 | TRPA1 (0.40) | ALDH1A1HPGD | |
| SCHEMBL19330846 | 0.76 | TRPA1 (0.40) | ALDH1A1HPGD | |
| SCHEMBL20535345 | 0.76 | MAPT (0.35) | ALDH1A1HPGDSTK39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | RHEB 1/4885ALDH1A1 3621/4885HPGD 1852/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | RHEB 1/4885ALDH1A1 3277/4885HPGD 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.